The drug developed by Biocad is designed for a single application. Theoretically, it adjusts the work of genes responsible for developing a blood clotting factor that can lead to long -term remission and even healing. In April 2025, the company sent a document for registration to the Ministry of Health.
Clinical studies of I-II phase have already been carried out with the participation of more than 20 patients with severe hemophilia V form. In Biocad, they note that this aspect is new for them and that there are more than six genetic preparations. If the registration is successful, this type of local medicine will be the first domestic medicine for the treatment of this disease.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
